GlassScriptPhysician profile
Lori O Cordial
NPI 1588855944
$1,511.74
in general payments reported to CMS, 2019-2025
23 companies · $18.92 in 2025
The $18.92 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $193 · 2021: $383 · 2022: $331 · 2023: $279 · 2024: $67.84 · 2025: $18.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $229.76 | 2021-2025 | Farxiga, Airsupra |
| Pfizer INC. | $153.19 | 2019-2023 | |
| Astellas Pharma US INC | $140.07 | 2021-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.59 | 2020-2023 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $109.57 | 2019-2024 | Linzess |
| Abbvie INC. | $105.62 | 2019-2022 | |
| Lilly USA, LLC | $98.90 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.27 | 2019-2021 | |
| Amgen INC. | $94.49 | 2019-2024 | Otezla, Repatha |
| Sanofi Pasteur INC. | $57.50 | 2020 | |
| Glaxosmithkline, LLC. | $51.03 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $38.17 | 2019-2020 | |
| Novo Nordisk INC | $34.86 | 2020-2021 | |
| Amarin Pharma, INC. | $27.02 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $26.51 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.78 | 2022 | |
| Mckesson Medical-Surgical, INC. | $20.00 | 2021 | |
| Eisai INC. | $18.32 | 2022 | |
| Ibsa Pharma INC. | $17.87 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.23 | 2021 | |
| Shire North American Group INC | $15.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.08 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.91 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Cordial listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.